FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa
- January 3, 2019
- 0
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
Source link
